Zeda announced today that it agreed to acquire The Orthopaedic Implant Company (OIC) for an undisclosed amount.
San Francisco-based Zeda says the acquisition marks a “significant leap forward” in strengthening its commitment to “revolutionizing manufacturing and distribution of medical devices globally.”
OIC delivers high-quality, cost-effective orthopedic devices, Zeda said in a news release. The company believes the acquisitions enables it to produce OIC’s implant designs, fortifying and accelerating its mission to provide accessible, high-value trauma implants to patients.
Itai Nemovicher, OIC co-founder and CEO, said Zeda shares the company’s values in advancing access to critical orthopedic care. Nemovicher said that, under Zeda, OIC could “reach new heights” in providing orthopedic solutions in the U.S. and abroad.
Under the terms of the acquisition, OIC will operate worldwide as a Zeda Health company. The company says the deal solidifies its position in the global orthopedic industry. It said it’s a company developing and using leading design and manufacturing technologies that push device design forward while improving affordability and access to care.
“The acquisition of OIC represents a pivotal moment for Zeda,” said CEO Shri Shetty. “Its leadership in value-based implants perfectly complements our additive manufacturing technologies that can deliver high-quality orthopedic devices and implants that are accessible to all patients, regardless of country and socioeconomic status. Together, our strengths and expertise will raise the standard of care globally and equitably for the world’s entire population.”